Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag in Chronic ITP
NCT00441090Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avatrombopag in immune thrombocytopenia (ITP) (5 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Responder Rate (RR) to Avatrombopag at Day 28. Started Feb 2007; status: completed.
02
Drugs
avatrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT00441090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00441090.